These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 35420123)

  • 1. Definitive outcomes in patients with rifampicin-resistant tuberculosis treated in Niger from 2012 to 2019: A retrospective cohort study.
    Souleymane MB; Decroo T; Mamadou S; Soumana A; Lawan IM; Gagara-Issoufou A; Adehossi E; Ortuño-Gutiérrez N; Lynen L; Rigouts L; de Jong BC; Van Deun A; Piubello A
    Int Health; 2023 May; 15(3):258-264. PubMed ID: 35420123
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effectiveness and safety of bedaquiline-containing regimens for treatment on patients with refractory RR/MDR/XDR-tuberculosis: a retrospective cohort study in East China.
    Zhang SJ; Yang Y; Sun WW; Zhang ZS; Xiao HP; Li YP; Zhang ZM; Fan L
    BMC Infect Dis; 2022 Aug; 22(1):715. PubMed ID: 36038829
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Management of multidrug-resistant tuberculosis with shorter treatment regimen in Niger: Nationwide programmatic achievements.
    Piubello A; Souleymane MB; Hassane-Harouna S; Yacouba A; Lempens P; Assao-Neino MM; Maman-Lawan I; Attaher S; Moustapha B; Soumana A; Gagara-Issoufou A; Ortuño-Gutiérrez N; Roggi A; Gumusboga M; Hamidou-Harouna Z; Dockx J; Mamadou S; de Jong BC; Decroo T; Van Deun A
    Respir Med; 2020 Jan; 161():105844. PubMed ID: 32056722
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety, effectiveness, and adherence of a short and all-oral treatment regimen for the treatment of rifampicin-resistant tuberculosis in Niger: a study protocol of a pragmatic randomised clinical trial with stratified block randomisation.
    Souleymane MB; Decroo T; Soumana A; Maman Lawan I; Gagara-Issoufou A; Halidou-Moussa S; Ortuño-Gutiérrez N; Adehossi E; Mamadou S; Van Deun A; Piubello A
    Trials; 2022 Dec; 23(1):1011. PubMed ID: 36514153
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Principles of chemotherapy for tuberculosis in national tuberculosis programmes of low- and middle-income countries.
    Chiang CY; Lin CJ
    Indian J Tuberc; 2020 Dec; 67(4S):S16-S22. PubMed ID: 33308663
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Primary bedaquiline resistance in Karakalpakstan, Uzbekistan.
    Moe S; Rekart ML; Hernandez D; Sholpan A; Ismailov A; Oluya M; Bayniyazova A; Zinaida T; Nargiza P; Gomez-Restrepo C; Sitali N; Sinha A
    Int J Tuberc Lung Dis; 2023 May; 27(5):381-386. PubMed ID: 37143220
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Drug-resistant pulmonary tuberculosis at Maradi Regional Hospital Center, Niger (2014-2018)].
    Harouna Amadou ML; Maman Lawan I; Abdoulaye O; Ibrahim Mamadou AK; Amadou O; Boureima H; Ahamadou B; Hama Aghali N; Abdourahamane Maifada NH; Kabirou Amoussa A; Maidakouale C
    Med Trop Sante Int; 2023 Dec; 3(4):. PubMed ID: 38390008
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effectiveness of bedaquiline containing all oral longer regimens in treating multidrug/rifampicin resistant tuberculosis in Pakistan.
    Khan A; Khan AH; Ahmad N; Ghafoor A
    J Infect Public Health; 2024 Sep; 17(9):102522. PubMed ID: 39173557
    [TBL] [Abstract][Full Text] [Related]  

  • 9.
    Indarti HT; Kristin E; Soedarsono S; Endarti D
    Int J Mycobacteriol; 2022; 11(3):261-267. PubMed ID: 36260444
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment outcomes 24 months after initiating short, all-oral bedaquiline-containing or injectable-containing rifampicin-resistant tuberculosis treatment regimens in South Africa: a retrospective cohort study.
    Ndjeka N; Campbell JR; Meintjes G; Maartens G; Schaaf HS; Hughes J; Padanilam X; Reuter A; Romero R; Ismail F; Enwerem M; Ferreira H; Conradie F; Naidoo K; Menzies D
    Lancet Infect Dis; 2022 Jul; 22(7):1042-1051. PubMed ID: 35512718
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Programmatic management of rifampicin-resistant tuberculosis with standard regimen in Cameroon: a retrospective cohort study.
    Jouego CG; Gils T; Piubello A; Mbassa V; Kuate A; Ngono A; Belinga E; Etoundi A; Tollo A; Makondi D; André E; Masumbe P; Lynen L; Noeske J; Decroo T
    Int J Infect Dis; 2022 Nov; 124():81-88. PubMed ID: 36108960
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Translating drug resistant tuberculosis treatment guidelines to reality in war-torn Kandahar, Afghanistan: A retrospective cohort study.
    Mesic A; Khan WH; Lenglet A; Lynen L; Ishaq S; Phyu EHH; Mar HT; Oraegbu A; Seddiq MK; Amirzada HK; Fernhout J; Kamau C; Ariti C; Gomez D; Decroo T
    PLoS One; 2020; 15(8):e0237787. PubMed ID: 32822375
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of the all-oral bedaquiline-containing regimen as treatment for pediatric multidrug/rifampicin-resistant tuberculosis: a multicenter, retrospective, cohort study.
    Sun WW; Yang M; Chen XH; Fan LC; Wu HY; Zhang SJ; Chen Y; Fan L
    Expert Rev Anti Infect Ther; 2024 Apr; 22(4):219-227. PubMed ID: 37982155
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bedaquiline resistance probability to guide treatment decision making for rifampicin-resistant tuberculosis: insights from a qualitative study.
    Tu PHT; Anlay DZ; Dippenaar A; Conceição EC; Loos J; Van Rie A
    BMC Infect Dis; 2022 Nov; 22(1):876. PubMed ID: 36418994
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and Effectiveness Outcomes From a 14-Country Cohort of Patients With Multi-Drug Resistant Tuberculosis Treated Concomitantly With Bedaquiline, Delamanid, and Other Second-Line Drugs.
    Huerga H; Khan U; Bastard M; Mitnick CD; Lachenal N; Khan PY; Seung KJ; Melikyan N; Ahmed S; Rich ML; Varaine F; Osso E; Rashitov M; Salahuddin N; Salia G; Sánchez E; Serobyan A; Rafi Siddiqui M; Grium Tefera D; Vetushko D; Yeghiazaryan L; Holtzman D; Islam S; Kumsa A; Jacques Leblanc G; Leonovich O; Mamsa S; Manzur-Ul-Alam M; Myint Z; Padayachee S; Franke MF; Hewison C
    Clin Infect Dis; 2022 Oct; 75(8):1307-1314. PubMed ID: 35243494
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Standard short-course chemotherapy for drug-resistant tuberculosis: treatment outcomes in 6 countries.
    Espinal MA; Kim SJ; Suarez PG; Kam KM; Khomenko AG; Migliori GB; Baéz J; Kochi A; Dye C; Raviglione MC
    JAMA; 2000 May; 283(19):2537-45. PubMed ID: 10815117
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Superior Efficacy of a TBI-166, Bedaquiline, and Pyrazinamide Combination Regimen in a Murine Model of Tuberculosis.
    Ding Y; Zhu H; Fu L; Zhang W; Wang B; Guo S; Chen X; Wang N; Liu H; Lu Y
    Antimicrob Agents Chemother; 2022 Sep; 66(9):e0065822. PubMed ID: 35924925
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Better programmatic outcome with the shorter regimen for the treatment of multidrug-resistant tuberculosis (MDR-TB) in Guinea: A retrospective cohort study.
    Hassane-Harouna S; Cherif GF; Ortuno-Gutierrez N; Cisse D; Camara LM; Diallo BD; Camara S; Bangoura AM; Lynen L; Decroo T
    PLoS One; 2020; 15(8):e0237355. PubMed ID: 32776969
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The perceived impact of isoniazid resistance on outcome of first-line rifampicin-throughout regimens is largely due to missed rifampicin resistance.
    Van Deun A; Decroo T; Kya Jai Maug A; Hossain MA; Gumusboga M; Mulders W; Ortuño-Gutiérrez N; Lynen L; de Jong BC; Rieder HL
    PLoS One; 2020; 15(5):e0233500. PubMed ID: 32421749
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Characteristics and treatment outcomes of INH-resistant or RFP-resistant tuberculosis].
    Saito W; Nagayama N; Miyamoto M; Hara H; Suzuki J; Masuda K; Baba M; Tamura A; Nagai H; Akagawa S; Kawabe Y; Machida K; Kurashima A; Yotsumoto H
    Kekkaku; 2003 Oct; 78(10):611-7. PubMed ID: 14621568
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.